Sign In
Buy AKBA
$0.97
+0.0333 (+3.56%)
At Close: Jun 03, 2026
U.S. FDA approves Akebia's anemia drug
08:45pm, Wednesday, 27'th Mar 2024
The U.S. Food and Drug Administration approved Akebia Therapeutics' drug to treat anemia caused by chronic kidney disease in dialysis patients, the drugmaker said on Wednesday.
Once-Daily Oral HIF-PH Inhibitor Activates Physiologic Response to Manage Anemia Akebia's Launch Strategy Developed to Drive Toward a Potential New Oral Standard of Care Company to Host Conference C
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4
06:31pm, Thursday, 14'th Mar 2024
Akebia Therapeutics (AKBA) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.04 per share a year ago.
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
04:15pm, Thursday, 14'th Mar 2024
Potential vadadustat U.S. approval on PDUFA date of March 27, 2024 Strengthened balance sheet with $55.0 million term loan financing and $26.0 million in proceeds from ATM Reported 2023 Auryxia (fer
Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
05:05pm, Monday, 11'th Mar 2024
CAMBRIDGE, Mass. , March 11, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, t
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 01'st Mar 2024
CAMBRIDGE, Mass. , March 1, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, grante
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 02'nd Feb 2024
CAMBRIDGE, Mass. , Feb. 2, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, grant
Akebia Secures $55 Million Term Loan Financing
08:00am, Tuesday, 30'th Jan 2024
Strengthens Balance Sheet Ahead of Potential Vadadustat Approval on March 27, 2024 CAMBRIDGE, Mass. , Jan. 30, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical co
Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer
08:30am, Tuesday, 09'th Jan 2024
CAMBRIDGE, Mass. , Jan. 9, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, tod
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Tuesday, 02'nd Jan 2024
CAMBRIDGE, Mass. , Jan. 2, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, grant
Akebia Therapeutics to Present at Piper Sandler Healthcare Conference
08:00am, Monday, 20'th Nov 2023
CAMBRIDGE, Mass. , Nov. 20, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, toda
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
11:20am, Thursday, 26'th Oct 2023
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Penny Stocks To Buy According To Analysts, Targets Up To 1,494%
03:12pm, Monday, 28'th Aug 2023
If you're looking to gain an edge in the stock market today, you've got to have more than a list of penny stocks to watch. You need to understand how to use the wild volatility that has been created t
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
11:16am, Friday, 25'th Aug 2023
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.23 per share a year ago.
Akebia Therapeutics to Report Second Quarter Financial Results and Discuss Recent Business Highlights
04:35pm, Wednesday, 23'rd Aug 2023
Akebia to Host Conference Call on August 25 th at 9:00 a.m. ET CAMBRIDGE, Mass.
